Scribe Therapeutics Files for Nasdaq IPO as It Advances CRISPR-Based LDL-C Program
Scribe Therapeutics has filed for a proposed initial public offering on Nasdaq. The clinical-stage biotechnology firm is developing in vivo CRISPR technologies aimed at preventing and treating common diseases, with an initial emphasis on cardiovascular and metabolic conditions. Its lead candidate, STX-1150, employs the company's ELXR epigenetic sil…